PDCD1 and neoplasm: These discrepancies may be attributed to differences in PD-L1 expression levels, tumor mutational burden, and other biomarkers that influence response to checkpoint inhibition, which aligns with previous findings that PD-1 blockade is particularly effective in tumors with high PD-L1 expression [29].